RxDoctor Payments Data

Mahesh Moondra, MD

Internal Medicine · Salisbury, MDNPI 1912932237

Payments from drug & device makers

$1,773in general payments, 2019–2025

Across 94 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$441
  • Astellas Pharma US Inc$160
  • AbbVie$152
  • Amgen$145
  • Lilly USA, LLC$141
  • Novartis$135
  • plus $600 from 14 others

What the payments were for

  • Speaking & faculty fees$151%
  • Food & beverage$1,62892%
  • Education$1307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,773 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$162,400
Medicare patients
324
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate69$69,187
OzempicSemaglutide57$59,778
JardianceEmpagliflozin55$54,473
EliquisApixaban50$49,632
XareltoRivaroxaban38$40,535
Synjardy XrEmpagliflozin/Metformin Hcl25$27,435
CreonLipase/Protease/Amylase13$26,236
FarxigaDapagliflozin Propanediol24$22,978
TrulicityDulaglutide21$21,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,329
Rosuvastatin Calcium337$12,461
Advair HfaFluticasone Propion/Salmeterol17$9,746
Breo ElliptaFluticasone/Vilanterol16$8,732
Atorvastatin Calcium380$6,030
Metoprolol Succinate213$3,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$82$81,90980 claims
MerckJanuvia$13$69,18769 claims
Novo NordiskOzempic$41$59,77857 claims
PfizerEliquis$107$49,63250 claims
Johnson & JohnsonXarelto$27$40,53538 claims
AbbVieCreon$152$26,23613 claims
GSKTrelegy Ellipta, Breo Ellipta$70$25,06136 claims
AstraZenecaFarxiga$441$22,97824 claims
Lilly USA, LLCTrulicity$141$21,02221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →